Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897520387> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W2897520387 endingPage "e675" @default.
- W2897520387 startingPage "e675" @default.
- W2897520387 abstract "Non-small cell lung cancer (NSCLC) represents approximately 75% of the histological types of lung cancer. In patients with oligometastatic NSCLC, definitive treatment to primary tumor and low thoracic tumor burden are associated with better outcomes. The use of stereotactic ablative radiotherapy (SABR) has demonstrated high rates of local control for lung metastases and long-term survival improvement. The aim of this study is to evaluate Local Control (LC), Progression Free Survival (PFS) and toxicity of patients with oligometastatic NSCLC treated with SABR. A prospective study was conducted with oligometastatic NSCLC patients. From July 2016 to December 2017, with a median follow up of 21.7 months, eighteen patients were enrolled. All patients received systemic therapy, those with partial response (PR), assessed by PET CT, were referred for SABR treatment (45-60 Gy in 3-7 fractions) to the thoracic lesion (primary or metastatic) depending on location, size and number of lesions, always keeping BED (Biologically Effective Dose) >100 Gy for tumor. Eighteen patients were treated with SABR, response to treatment was as follows: global response was 94%, partial response 22% and complete response 72.2%. Mean time to progression after SABR treatment was 7.04 months (CI 95% 0.27-17.84 months). Progression free survival since beginning of any treatment was 20.14 months (CI 95% 12.92 - 27.35 months). The pattern of recurrence/progression was as follows: local (in field) 1/18, regional (mediastinal lymph node) 1/18 and systemic 4/18, 12/18 did not show any recurrence. Sixteen patients developed grade 1 pneumonitis; one patient developed grade 2 pneumonitis and grade 3 pneumonitis was reported in one patient. Only three patients required treatment with steroids (16.7%). SABR is a suitable and well-tolerated therapeutic option for patients with oligometastatic NSCLC. SABR have shown to improve local control and increase progression-free survival. Future clinical trials are required to fully evaluate the effects of this treatment." @default.
- W2897520387 created "2018-10-26" @default.
- W2897520387 creator A5004226767 @default.
- W2897520387 creator A5007203774 @default.
- W2897520387 creator A5012806163 @default.
- W2897520387 creator A5020080512 @default.
- W2897520387 creator A5024670184 @default.
- W2897520387 creator A5028611685 @default.
- W2897520387 creator A5032472383 @default.
- W2897520387 creator A5035063101 @default.
- W2897520387 creator A5037000397 @default.
- W2897520387 creator A5046623193 @default.
- W2897520387 creator A5054742415 @default.
- W2897520387 creator A5062054017 @default.
- W2897520387 creator A5062097300 @default.
- W2897520387 date "2018-11-01" @default.
- W2897520387 modified "2023-10-16" @default.
- W2897520387 title "Stereotactic Ablative Radiation Therapy Improves Progression-free Survival and Local Control In Patients with Oligometastatic Lung Cancer" @default.
- W2897520387 doi "https://doi.org/10.1016/j.ijrobp.2018.07.1822" @default.
- W2897520387 hasPublicationYear "2018" @default.
- W2897520387 type Work @default.
- W2897520387 sameAs 2897520387 @default.
- W2897520387 citedByCount "0" @default.
- W2897520387 crossrefType "journal-article" @default.
- W2897520387 hasAuthorship W2897520387A5004226767 @default.
- W2897520387 hasAuthorship W2897520387A5007203774 @default.
- W2897520387 hasAuthorship W2897520387A5012806163 @default.
- W2897520387 hasAuthorship W2897520387A5020080512 @default.
- W2897520387 hasAuthorship W2897520387A5024670184 @default.
- W2897520387 hasAuthorship W2897520387A5028611685 @default.
- W2897520387 hasAuthorship W2897520387A5032472383 @default.
- W2897520387 hasAuthorship W2897520387A5035063101 @default.
- W2897520387 hasAuthorship W2897520387A5037000397 @default.
- W2897520387 hasAuthorship W2897520387A5046623193 @default.
- W2897520387 hasAuthorship W2897520387A5054742415 @default.
- W2897520387 hasAuthorship W2897520387A5062054017 @default.
- W2897520387 hasAuthorship W2897520387A5062097300 @default.
- W2897520387 hasBestOaLocation W28975203871 @default.
- W2897520387 hasConcept C106159729 @default.
- W2897520387 hasConcept C121608353 @default.
- W2897520387 hasConcept C126322002 @default.
- W2897520387 hasConcept C126838900 @default.
- W2897520387 hasConcept C141071460 @default.
- W2897520387 hasConcept C143998085 @default.
- W2897520387 hasConcept C162324750 @default.
- W2897520387 hasConcept C187625094 @default.
- W2897520387 hasConcept C19617505 @default.
- W2897520387 hasConcept C2776256026 @default.
- W2897520387 hasConcept C2776694085 @default.
- W2897520387 hasConcept C2777714996 @default.
- W2897520387 hasConcept C2780387249 @default.
- W2897520387 hasConcept C2780739268 @default.
- W2897520387 hasConcept C509974204 @default.
- W2897520387 hasConcept C71924100 @default.
- W2897520387 hasConcept C85393063 @default.
- W2897520387 hasConcept C91602232 @default.
- W2897520387 hasConceptScore W2897520387C106159729 @default.
- W2897520387 hasConceptScore W2897520387C121608353 @default.
- W2897520387 hasConceptScore W2897520387C126322002 @default.
- W2897520387 hasConceptScore W2897520387C126838900 @default.
- W2897520387 hasConceptScore W2897520387C141071460 @default.
- W2897520387 hasConceptScore W2897520387C143998085 @default.
- W2897520387 hasConceptScore W2897520387C162324750 @default.
- W2897520387 hasConceptScore W2897520387C187625094 @default.
- W2897520387 hasConceptScore W2897520387C19617505 @default.
- W2897520387 hasConceptScore W2897520387C2776256026 @default.
- W2897520387 hasConceptScore W2897520387C2776694085 @default.
- W2897520387 hasConceptScore W2897520387C2777714996 @default.
- W2897520387 hasConceptScore W2897520387C2780387249 @default.
- W2897520387 hasConceptScore W2897520387C2780739268 @default.
- W2897520387 hasConceptScore W2897520387C509974204 @default.
- W2897520387 hasConceptScore W2897520387C71924100 @default.
- W2897520387 hasConceptScore W2897520387C85393063 @default.
- W2897520387 hasConceptScore W2897520387C91602232 @default.
- W2897520387 hasIssue "3" @default.
- W2897520387 hasLocation W28975203871 @default.
- W2897520387 hasOpenAccess W2897520387 @default.
- W2897520387 hasPrimaryLocation W28975203871 @default.
- W2897520387 hasRelatedWork W1999715968 @default.
- W2897520387 hasRelatedWork W2468978631 @default.
- W2897520387 hasRelatedWork W2559911131 @default.
- W2897520387 hasRelatedWork W2794068552 @default.
- W2897520387 hasRelatedWork W2944489288 @default.
- W2897520387 hasRelatedWork W2972953288 @default.
- W2897520387 hasRelatedWork W3029134866 @default.
- W2897520387 hasRelatedWork W4310082075 @default.
- W2897520387 hasRelatedWork W4367841621 @default.
- W2897520387 hasRelatedWork W2777338963 @default.
- W2897520387 hasVolume "102" @default.
- W2897520387 isParatext "false" @default.
- W2897520387 isRetracted "false" @default.
- W2897520387 magId "2897520387" @default.
- W2897520387 workType "article" @default.